OCCIDENT — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Resistellresistell.cominDec 2022
Resistell develops a nanomotion-based diagnostic device for rapid phenotypic antibiotic susceptibility testing (AST), aimed at accelerating detection of antibiotic resistance in hospital settings.
BiotechHealthtechMedical Devices
Dr. Danuta Cichocka(CEO, Co-Founder, Board Member)inGrzegorz Gonciarz(COO)inDr. Alex Sturm(Chief Scientific Officer)inMartin Birk(CFO)in
Co-investorsAlpana VenturesTRUMPF Venture
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.